Gilead Sciences, Inc. (NASDAQ:GILD) was the recipient of some unusual options trading on Wednesday. Stock traders bought 12,287 put options on the company. This represents an increase of approximately 106% compared to the typical daily volume of 5,952 put options.

GILD has been the topic of several research analyst reports. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 target price on the stock in a research report on Tuesday, April 18th. Jefferies Group LLC restated a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, April 6th. J P Morgan Chase & Co restated an “overweight” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, April 6th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a research report on Tuesday, May 2nd. Finally, Barclays PLC restated an “overweight” rating and set a $85.00 target price (down previously from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $80.58.

In other Gilead Sciences news, Director John Francis Cogan sold 9,943 shares of the company’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the sale, the director now owns 47,562 shares in the company, valued at approximately $3,198,544.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $67.18, for a total value of $4,926,510.94. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at approximately $214,973,917.42. The disclosure for this sale can be found here. Insiders sold a total of 88,276 shares of company stock worth $5,932,578 in the last quarter. Corporate insiders own 1.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. Keel Point LLC increased its position in Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 11 shares during the period. Terril Brothers Inc. increased its position in Gilead Sciences by 0.3% in the first quarter. Terril Brothers Inc. now owns 8,957 shares of the biopharmaceutical company’s stock valued at $608,000 after buying an additional 31 shares during the period. Fayerweather Charles increased its position in Gilead Sciences by 0.5% in the first quarter. Fayerweather Charles now owns 7,092 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 35 shares during the period. Sullivan Bruyette Speros & Blaney LLC increased its position in Gilead Sciences by 0.6% in the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 6,779 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 42 shares during the period. Finally, Bluestein R H & Co. increased its position in Gilead Sciences by 1.2% in the fourth quarter. Bluestein R H & Co. now owns 3,665 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 45 shares during the period. 73.99% of the stock is owned by institutional investors and hedge funds.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 70.52 on Friday. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $88.85. The company has a 50 day moving average price of $65.46 and a 200-day moving average price of $69.00. The stock has a market cap of $92.15 billion, a P/E ratio of 7.45 and a beta of 1.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, beating the consensus estimate of $2.18 by $0.02. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.66 billion. On average, equities research analysts predict that Gilead Sciences will post $8.35 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Shareholders of record on Friday, June 16th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 21.99%.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/24/gilead-sciences-sees-unusually-large-options-volume-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.